详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]GCP Center/Institute of Drug Clinical Trials, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [2]Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [3]Institute of Pharmacy, North Sichuan Medical College, Nanchong, China. [4]Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [5]Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

出处：

DOI：

摘要：

The ability of colorectal cancer (CRC) cells to escape from natural killer (NK) cell immune surveillance leads to anti-tumor treatment failure. The long non-coding RNA (lncRNA) ELFN1-AS1 is aberrantly expressed in multiple tumors suggesting a role as an oncogene in cancer development. However, whether ELFN1-AS1 regulates immune surveillance in CRC is unclear. Here, we determined that ELFN1-AS1 enhanced the ability of CRC cells to escape from NK cell surveillance in vitro and in vivo. In addition, we confirmed that ELFN1-AS1 in CRC cells attenuated the activity of NK cell by down-regulating NKG2D and GZMB via the GDF15/JNK pathway. Furthermore, mechanistic investigations demonstrated that ELFN1-AS1 enhanced the interaction between the GCN5 and SND1 protein and this influenced H3k9ac enrichment at the GDF15 promotor to stimulate GDF15 production in CRC cells. Taken together, our findings indicate that ELFN1-AS1 in CRC cells suppresses NK cell cytotoxicity and ELFN1-AS1 is a potential therapeutic target for CRC.© 2023. The Author(s).

基金：

语种：

PubmedID：

第一作者：

第一作者机构： [1]GCP Center/Institute of Drug Clinical Trials, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [2]Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [3]Institute of Pharmacy, North Sichuan Medical College, Nanchong, China.

共同第一作者：

通讯作者：

通讯机构： [1]GCP Center/Institute of Drug Clinical Trials, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [2]Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. [3]Institute of Pharmacy, North Sichuan Medical College, Nanchong, China. [5]Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：